The effects of the JAK inhibitor baricitinib (Olumiant) waned after treatment was stopped among patients with new-onset type ...

Glycogen phosphorylase (GP) is a pivotal enzyme responsible for the catabolism of glycogen into glucose, a process intricately linked to blood glucose regulation. In the context of type 2 diabetes, ...

Over 3 years, SGLT2 inhibitors were safely associated with a nearly one third reduction in the risk for serious liver events.

An analysis of real-world data from a single medical center is providing insight into the effects of off-label glucagon-like peptide 1 (GLP-1) receptor agonist (RA) and sodium-glucose cotransporter-2 ...

ASCO 2021 brings us news of RELATIVITY-047, which tested the combination of anti-PD-1 nivolumab with a drug called relatlimab that is an inhibitor of the lymphocyte activation gene-3 (LAG-3) pathway.

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio NEW ORLEANS — A novel “counterintuitive” ...

Type 2 diabetes (T2DM), affecting more than 530 million worldwide, is a metabolic disease often coupled with cardiovascular complications including coronary artery disease, heart failure, and ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Receipt of an SGLT-2 inhibitor for type 2 diabetes in ...

The Janus kinase (JAK) inhibitor ruxolitinib (Jakafi) eased the severe inflammatory and dermatologic symptoms of disabling pansclerotic morphea (DPM), an initial clinical series showed. After a series ...